Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice

Blood

Volumn 126, Issue 22, 2015, Pages 2511-2517

  Barazia, Andrew ^a   Li, Jing ^a   Kim, Kyungho ^a   Shabrani, Namrata ^a   Cho, Jaehyung ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKTI XII; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AKT2 PROTEIN, MOUSE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CELL ADHESION; CELL HYPOXIA; CELL INTERACTION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE MICROSCOPY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; SHORT COURSE THERAPY; SICKLE CELL ANEMIA; SURVIVAL; THROMBOCYTE AGGREGATION; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; VASCULAR DISEASES;

ANEMIA, SICKLE CELL; ANIMALS; E-SELECTIN; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE-1; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 84948779653     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-626234     Document Type: Article

References (33)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11): 762-769.
2. Pauling L, Itano HA, et al. Sickle cell anemia a molecular disease. Science. 1949;110(2865): 543-548.
3. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364(9442):1343-1360.
4. Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(4): L314-L324.
5. Li J, Kim K, Hahm E, et al. Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation. J Clin Invest. 2014;124(4): 1483-1496.
6. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123(24): 3818-3827.
7. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood. 2012;120(18): 3647-3656.
8. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656.
9. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111(2): 231-239.
10. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy. Hematology. 2000;5(4):335-339.
11. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug? J Thromb Haemost. 2006;4(12):2593-2598.
12. Almeida CB, Scheiermann C, Jang JE, et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood. 2012; 120(14):2879-2888.
13. Li J, Kim K, Barazia A, Tseng A, Cho J. Platelet-neutrophil interactions under thromboinflammatory conditions. Cell Mol Life Sci. 2015;72(14):2627-2643.
14. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15(4): 384-391.
15. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004; 113(3):441-450.
16. Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010;116(10):1779-1786.
17. Ghosh S, Tan F, Ofori-Acquah SF. Spatiotemporal dysfunction of the vascular permeability barrier in transgenic mice with sickle cell disease. Anemia. 2012;2012:582018.
18. Polanowska-Grabowska R, Wallace K, Field JJ, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010;30(12):2392-2399.
19. Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med. 2011;17(11):1381-1390.
20. Lindemann S, Sharafi M, Spiecker M, et al. NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1 mRNA and surface expression. Thromb Res. 2000;97(3):113-123.
21. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol. 2007; 151(3):305-321.
22. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med. 2008;44(8): 1506-1528.
23. Dasgupta T, Fabry ME, Kaul DK. Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. Am J Physiol Regul Integr Comp Physiol. 2010;298(2): R394-R402.
24. Reiter CD, Wang X, Tanus-Santos JE, et al. Cellfree hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12): 1383-1389.
25. Chen J, Tang H, Hay N, Xu J, Ye RD. Akt isoforms differentially regulate neutrophil functions. Blood. 2010;115(21):4237-4246.
26. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-29-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102(12):3865-3870.
27. Kutlar A, Ataga K, Reid M, et al. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2012;87(11):1017-1021.
28. Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125(17): 2656-2664.
29. Wun T, Soulieres D, Frelinger AL, et al. A doubleblind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
30. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2): 392-396.
31. Daak AA, Ghebremeskel K, Hassan Z, et al. Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2013;97(1):37-44.
32. Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol. 2003;73(1):26-32.
33. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728-1731.